Needham downgrades Hologic (Nasdaq: HOLX) from Buy to Hold, saying they are concerned the company will miss Q4 revenue guidance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE